No Data
Atossa Therapeutics Doses First Patient in Breast Cancer Therapy Study
Express News | Atossa Therapeutics: Data From Study Anticipated in 2026
Express News | Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-Spy 2 Trial Combining (Z)-Endoxifen With Abemaciclib for Er+/Her2- Breast Cancer
Express News | Atossa Therapeutics And Quantum Leap Healthcare Collaborative Dose First Patient In Clinical Trial Evaluating (Z)-Endoxifen With Abemaciclib As Neoadjuvant Treatment For High-Risk ER+/HER2- Breast Cancer
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen With Abemaciclib for ER+/HER2- Breast Cancer
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations
tian liang : These few days
DJqualls : why?
5060 OP DJqualls : do your own work!!!